抗肿瘤药物吉非替尼专利技术分析  

Analysis of the patent technology for the anti-tumor drug gefitinib

作　　者：陈昊[1] 

机构地区：[1]国家知识产权局专利局专利审查协作江苏中心,苏州215163

出　　处：《中国新药杂志》2015年第12期1326-1333,1348,共9页Chinese Journal of New Drugs

摘　　要：小分子酪氨酸激酶抑制剂(替尼类药物)作为新的靶向抗肿瘤药物,是近年来抗肿瘤药物研究的热点,此类药物已有多个上市,其为临床治疗肿瘤提供了更多的选择。吉非替尼作为此类药物的代表,在临床上应用广泛,效果良好。本文从这类药物中最具代表性的吉非替尼入手,对吉非替尼相关专利申请状况进行了分析,并重点对吉非替尼的专利技术发展路线进行了介绍,还对重要申请人的专利申请发展路线进行了梳理,在此基础上为国内研发机构和相关企业对于吉非替尼的后期开发、专利保护策略以及知识产权布局提供有益的参考和建议。As a new kind of targeted anti-tumor drug, the small molecular tyrosine kinase inhibitors have become the focus of the research and development of anti-tumor drugs in recent years. There have been several such drugs in the market, which provide more choices for the clinical treatment of cancer. Gefitinib, as a representative of such drugs, has been widely used in clinical practice and has a significant effect. In this article, we analyzed the patent application status and introduced the patent technology roadmap of gefitinib and also conducted a carding of its main applicants to provide some useful reference and recommendations on the development, patent protection countermeasure and intellectual property strategy of gefitinib for the domestic pharmaceutical enterprises.

关 键 词：吉非替尼 抗肿瘤药物 专利技术 专利分析 专利布局 

分 类 号：R979.1[医药卫生—药品]